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Introduction
After their initial misclassification as an opioid receptor subtype [1] , sigma receptors (σ-Rs) actually represent a non-opioid, non-phencyclidine but haloperidol-sensitive receptor family [2] .
To date, at least two distinct σ-Rs subtypes -designated as σ 1 and σ 2 [3] -have been pharmacologically characterized [4] [5] [6] . The amino acid sequence of the σ 1 receptor (σ1R) subtype was determined by purification and cloning from several animal species including man.
Interestingly, this receptor shows no homology with any mammalian protein, whilst it exhibits significant homology (30%) with sterol C 8 -C 7 isomerase from fungi [7, 8] . The σ1R has been associated with many diseases including stroke, cocaine addiction, pain, cancer, and neurodegenerative pathologies [9] .
On the other hand, the σ 2 receptor subtype has not been cloned yet, although its molecular weight has been determined as approximately 21.5 kDa. [7] It has been proposed that this σ-R subtype is involved in cellular apoptotic response [10, 11] , and in the release of Ca 2+ through an IP3-independent manner [12] [13] [14] .
To date, neither σ1R endogenous ligands have been definitively established [15] , nor the role of all σ1R ligands has been unequivocally established in terms of their agonistic or antagonistic receptor activity [9] . Ligands displaying preferential affinity for the σ1R subtype -and currently classified as σ1R agonists -are dextrorotatory benzomorphans such as (+)-pentazocine and (+)-N-allylnormetazocine (NANM, aka SKF-10,047), whereas haloperidol (categorized as σ1R
antagonist) and 1,3-di-(2-tolyl)guanidine (DTG) exhibit high affinity toward both receptor subtypes [15] . Given its very low affinity for the σ 2 receptors, (+)-pentazocine is now the "gold standard" molecule used, in its tritiated form, to label σ 1 receptors.
In our longstanding research in the field of σ1R ligands design and discovery, in 2009 we synthesized the series of benzoxazolone derivatives 1 ( Figure 1 ) characterized by high affinity and selectivity towards σ1receptor subtype [16, 17] . In particular, compounds 1a (H) and 1d showed the most interesting σ1R affinity within this molecular series, with K i σ 1 values of 2.6 nM and 7.1 nM and selectivity ratio (K i σ 2 /K i σ 1 ) of 46.2 and 5.1, respectively. Encouraged by these results, we then selected some of these molecules as training/test set compounds for the construction of a three-dimensional (3D)
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pharmacophore model for σ1R binding [17] , and the subsequent original development of a σ1R 3D homology model [18] , extensively validated in successive works [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . The information retrieved from the combined application of 3D pharmacophore modeling and molecular dynamics (MD)-based docking and scoring calculations using the 3D σ1R homology model allowed us to fully characterize the network of intermolecular interactions responsible for the potency of compounds 1 as σ1R binders.
In the quest of designing, synthesizing, and testing a second generation of effective σ1R binders, in this work we exploited this wealth of information at hand and explored the effect of the replacement of the benzoxazolone moiety in compounds 1 on σ1R affinity. Accordingly, based upon modeling design and predictions, a new series of substituted 1-(4-(aryl(methyl)amino)butyl)-heterocyclic derivatives 2-11 ( Figure 2 ) were synthesized and tested for σ1R binding affinity. Finally, the most promising compounds of this new molecular set were preliminary assessed for their activity profile (agonist/antagonist behavior) in a cell-based assay. 

Results and discussion
Computer-Aided Design of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic derivatives
Previous simulations performed on compounds 1a and 1d in complex with the 3D homology model of the σ1R [18, 19] led to the identification of a specific map of interaction for each functional group of these molecules, and to the recognition of the protein residues mainly involved in ligand binding. Yet, a detailed quantification of the interaction energies and the derivation of the relevant interaction spectra for these compounds -instrumental to complete the information set required for the design of new derivatives based on 1 -were not carried out at that time. Thus, the optimized structure of the benzoxazolone derivatives 1a and 1d were redocked in the binding pocket of the 3D σ1R model, and the corresponding protein/ligand free energy of binding (∆G bind ) were calculated via the MM/PBSA (Molecular Mechanics/PoissonBoltzmann Surface Area) approach [29] , yielding values in agreement with the previous report [17] , as expected (∆G bind = -10.59 kcal/mol for 1a, and -10.68 kcal/mol for 1d, respectively, Table SI1 ). Taking compound 1d as a proof-of-concept, the analysis of the equilibrated portion M A N U S C R I P T
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of the respective MD trajectory ( Figure 3A ) revealed in detail the qualitative pattern of the interactions between this compound and the σ1R, i.e., the engagement of the basic amine nitrogen of 1d in a persistent salt bridge with the COO-group of D126, and a stable hydrogen bond between the oxygen atom of the benzoxazolone ring of 1d and the -NH group of the peptidic bond linking residues T151 and V152 of the receptor. Moreover, the MD simulation accounts for the presence of stabilizing π−π interactions between the p-chlorobenzyl ring of 1d and the side chains of the protein amino acids W121 and R119 (see also Figure SI1 in the supplementary data). Finally, the aromatic fragment of the benzoxazolone moiety and the butyl linker chain of 1d are nestled in an hydrophobic pocket lined by the side chains of the receptor residues I128, F133, Y173 and L182, with the further stabilizing contribution of E172 ( Figure   3A ). 
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with an overall contribution of -6.34 kcal/mol. Contextually, the π interactions (π-cation and π-π, respectively) between the N-p-chlorobenzyl ring of 1d and the side chains of R119 and W121
produce an overall favorable contribution of -2.73 kcal/mol. Noteworthy, the polar interactions afforded by the receptor/ligand permanent salt bridge and hydrogen bond provide a favorable contribution to σ1R/1d binding of -5.46 kcal/mol.
On the basis of these results, we next proceeded with the design of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic derivatives potentially endowed with comparable, if not enhanced, σ1R affinity. To the purpose, we reasoned that the N-benzyl or the N-p-chlorobenzyl amine and the butyl spacer, with their corresponding interactions, were essential for effective σ1R binding. Thus, we decided to replace the benzoxazolone moiety with others, correlated, heterocyclic scaffolds, in order to explore the conformational space within the relevant binding cavity and to gain further information on the relevance of the specific intermolecular interactions. Accordingly, the following new molecular structures were selected to address an increased steric hindrance within the receptor cavity; (iii) the isoindoline-1,3-dione (8a,b) and indolin-2,3-dione (9a,b) rings were chosen as they are provided with two oxygen atoms, able to potentially perform mutual hydrogen bonds as acceptors with the receptors counterpart; and finally iv) the piperidin-2-one (10a,b) and the indole (11a,b) scaffolds were selected to study the role of the two peculiar pharmacophore features of the benzoxazolone substituent, i.e., its aromatic part and the hydrogen bond acceptor atom, respectively. In total, a set of 22 new compounds (2-11) was designed.
The same docking/MM-PBSA scoring computational procedure described for compounds 1a
and 1d was next applied to the optimized structures of 2-11 in complex with the σ1R (Table S1 ). Figure 4 shows the results of the MM/PBSA analysis, from which a direct structure-affinity correlation can be made. Figure 4 . In silico estimated free energies of binding (∆G bind ) for the newly designed set of 22 σ1R ligands in complex with receptor. The ∆G bind of the benzoxazolone derivatives 1a and 1d are also shown for comparison, the dotted red line serving as a guide.
As seen in Figure 4 , computational data predict that the replacement of the benzoxazolone moiety with a non-constrained analogous such as the 4-phenyloxazolidin-2-one group in On the other hand, the ∆G bind values predicted for compounds 4-7 point to a small decrease of σ1R binding capability for these molecules compared to the benzoxazolone derivatives 1a and Table   SI1 ). In fact, the presence of the amidic group in each scaffold allow them to perform the fundamental hydrogen bond with the receptor via their acceptor oxygen, while the aromatic fragment of the corresponding heterocyclic moiety can exploit stabilizing interactions while nicely encased within the σ1R hydrophobic cavity.
The results obtained with the remaining derivatives 8-11 deserved a more specific interpretation.
From a computational perspective, the lack of one of the important pharmacophore requirements in the piperidin-2-one (10a,b) and the indole (11a,b) derivatives leads to a plummet in the corresponding affinity for the σ1R, with a loss in ∆G bind of about 4 and 3 kcal/mol, respectively.
The absence of the aromatic fragment in the piperidinone derivatives 10a,b not only affects the hydrophobic interactions with the σ1R residues I128, F133, E172, Y173, and L182, but also, via a sort of domino effect, negatively reflects on the bound ligand conformation, with a consequent drastic reduction of the entire interaction spectrum, as testified in Figure 6 . The same behavior is reproduced by the indole derivatives 11a,b, for which not only the contributions of T151 and V152 are zero, as expected, but also the rest of the σ1R residues involved in ligand binding diminish their favorable contribution to binding enthalpy. 
Chemistry
All derivatives 2-11 were synthesized starting from the corresponding intermediate (Schemes 1 and 2), according to the synthetic pathway reported in Scheme 3 (Table SI2) In principle, the receptor binding studies on σ1R confirmed the structure-affinity relationship predicted by the computational approach, as testified from the strict correlation between the calculated free energies of binding and the corresponding K i σ1 values listed in Table 1 subtype, for which they show affinity values at least one order of magnitude lower with respect to the σ1R counterpart. The slight decrease in σ1R affinity predicted by modeling for compounds 4-7 as a consequence of the replacement of the benzoxazolone moiety with a larger heterocyclic group is confirmed by the corresponding experimental data (Table 1) . Interestingly, however, these molecules preserve a good selectivity profile against the σ2 subtype.
The experimental analysis carried out for the remaining new derivatives 8-11 confirmed that the absence of the fundamental heterocyclic groups dramatically affects receptor/ligand binding, the corresponding K i σ1 spanning the high nanomolar -micromolar concentration range.
It is interesting to note that, although the tested K i σ2 were very weak, all compounds show a similar behavior against the σ2R subtype, with affinity values all of the order of hundreds of nanomolar. The σ2 receptor is even more enigmatic than σ1R, and the information about its binding site for the ligands is exceedingly scares and fragmented; therefore any computational structure-affinity relationship derivation can be barely attempted, if at all. Anyway, on the basis of these results, we are be tempted to speculate that the σ2R region in which the heterocyclic scaffold is likely to be nestled might be characterized by higher adaptability with respect to σ1R, thereby accommodating the presence of different chemical moieties without requiring major energetical penalties. If verified, this information could be exploited in the future studies to investigate and rationalize the molecular determinants for the σ2R binding. Table 1 . σ1R and σ2R affinities of the synthesized compounds 2-11a,b. All compounds with highest affinities (<100 nM) were tested in triplicates. n.d.: not determined. The last row shows the correlation (R 2 =0.84) between the predicted values ∆G bind and the corresponding experimental ∆G bind,exp , calculated using the following relationship: ∆G bind,exp = -RT ln(1/K i σ 1 ).
Functional characterization
With the aim of performing an investigation of the cytotoxic activity of this new series of σ1R ligands, and attempting a preliminary functional characterization of their eventual agonist/antagonist profile, we compared the toxic effects of a set of novel compounds obtained on the SH-SY5Y neuroblastoma cell line with those measured for NE-100 and haloperidol (two commonly accepted σ1R antagonist) and pentazocine (the gold standard σ1R agonist) ( Figure   8 ). Although SH-SY5Y cells seem to express σ1R at moderate level [30] , previous works used this human cell line of neuronal origin for σ1R studies [31] [32] [33] and obtained results overlapping with those obtained with guinea pig brain subcellular fraction [34] .
To the purpose, we followed the approach originally proposed by Zeng et al. for σ2R ligands [35] , based on the MTT assay. The underlying assumption for performing these tests is that σ1R M A N U S C R I P T
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agonists should promote cytoprotection via target activation, while antagonists should be generally endowed with an opposite (i.e., cytotoxic) effect [36] . Specifically, we tested those new compounds characterized by the highest σ1R affinity (that is, 2b (R)-2b, (S)-2b, 3a, and 6a), while the lead compounds 1a and 1d were also tested for comparison.
Accordingly to its recognized antagonist profile, NE-100 has a potent cytotoxic effect, as clearly shown in Figure 9 , where the effect exerted by the best σ1R binders is also shown as % of NE-100 cytotoxicity at 50 µM (100%).
Considering the criteria adopted, the behavior of pentazocine and haloperidol in SH-SY5Y cells is consistent with an activity of agonist and antagonist compounds, respectively. Actually, haloperidol showed a cytotoxic effect (99%) at 50 µM strictly comparable with NE-100, while pentazocine exhibited a negligible cytotoxicity (4.4%) at the same concentration. The benzoxazolone derivatives 1a and 1d displayed an ambiguous cytotoxicity profile, since their corresponding values are comprised between 50% and 75%. Clearly, further investigations are required in this respect. On the other hand, the newly designed derivatives 2b (R)-2b, (S)-2b, 3a,
and 6a all exhibit a plausible σ1R agonist profile, seemingly in line with the low cytotoxic activity detected for pentazocine. In particular, the 4-phenyloxazolidin-2-one derivatives, both as pure enantiomers (R)-2b, (S)-2b and in their racemic form 2b, demonstrate very low cytotoxic effects (< 15%), strictly comparable to the prototypical σ1R agonist, as inferred from Figure 9 .
For the record, these compounds are also characterized by the best σ1R affinity along the new series of σ1R designed and tested in the present work (Table 1 ). . Cytotoxicity of σ1R ligands as obtained from the MTT assay. SH-SY5Y cells were treated with different σ1R ligands (50 µM) for 48h. MTT assay was then performed, cytotoxicity of compounds was determined, and data were reported as % of NE-100 cytotoxicity at 50 µM (100%). The bars represent the mean ± SD from three independent experiments performed in triplicate.
Conclusions
On the basis of the molecular information retrieved by the in silico analysis of the binding mode of the two lead benzoxazolone derivatives 1a and 1d, both endowed with high σ1R affinity (K i σ1 = 2.6 and 7.1 nM, respectively), we designed and synthesized the new series of derivatives 2-11a,b, with a twofold aim of (i) dissecting the effect of the replacement of the benzoxazolone moiety on sigma 1 receptor affinity, and (ii) preliminarily evaluating the behavior of these compounds as σ1R agonists or antagonists. All new molecules maintain the 1-(4-(aryl(methyl)amino)butyl)-spacer characterizing the compound series 1, whereas the benzoxazolone moiety, linked to the butyl chain, has been replaced with others, correlated, heterocyclic scaffolds to obtain the corresponding 4-phenyloxazolidin-2-one (2a,b, (R)-2a,b and
The results achieved by scoring the affinity of these molecules for the σ1R via their molecular dynamics simulations in complex with our 3D σ1R model allowed us to predict that, from the perspective of receptor binding ability, modifications of the benzoxazolone moiety are well tolerated only if the new molecular scaffolds preserve the peculiar molecular determinants for the optimal encasement in the relevant σ1R binding cavity. In fact, the new derivatives 2-7, in which the aromatic substituent and the hydrogen bond acceptor atom are preserved, display a binding capacity comparable to, or even slightly higher (as in the case of the derivatives 4-phenyloxazolidin-2-one 2a,b) to that of the lead compounds 1a and 1d. Conversely, when one of the pharmacophore requirements is missing (as in the piperidone (10a,b) or in the indole (11a,b) derivatives), the favorable interactions established between the σ1R and the ligand significantly decreases, with effects extending, in a domino effect, beyond the receptor hydrophobic cavity directly involved in ligand binding. Finally, it is interesting to highlight that the addition of a supplementary element, i.e. an additional hydrogen bond acceptor (e.g., isoindolindiones 8a,b and indolindiones 9a,b), leads to a substantial impairment of the resulting compound σ1R binding capability, by virtue of a suboptimal conformation of the aromatic fragment nestled in the receptor binding cavity.
All computer-based predictions were substantiated by the experimental characterization of the σ1R affinity of all new compounds through radioligand binding assays of the K i values against both sigma receptor subtypes. The analysis confirmed the quality of the in silico prediction with an outstanding agreement between the calculated σ1R affinity and the experimental inhibitory concentrations. Moreover, the experiments revealed a clear preference of the new derivative 2-7 for the σ1R with a good selectivity profile against the σ2 receptor subtypes.
Finally, the MTT viability assay on human neuroblastoma cells (SH-SY5Y) was performed in order to test the cytotoxic effects of the novel compounds. These data were also useful for a preliminary evaluation of the agonist/antagonist behavior on a selection of the best σ1R binder in the new series. According to these tests, the new 4-phenyloxazolidin-2-one derivatives 2b, (R)-2b and (S)-2b demonstrated a very low level of cytotoxicity, comparable with that obtained with the σ1R prototypical agonist pentazocine. This property, coupled with their remarkable σ1R affinities (K i σ1 values in the low nanomolar range), outlines these compounds as the most M A N U S C R I P T
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promising candidates of the series to exploit them as new pharmacologic agents for further and more specific investigation on the σ1R biologic activity.
Experimental
Computational details
The optimized structure of all compounds was docked into the putative binding pockets for the sigma1 receptor by applying a consolidated procedure [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] with AutoDock 4.2 [37] . For each compound, only the molecular conformation satisfying the combined criteria of having the lowest (i.e., more favorable) Autodock energy and belonging to a highly populated cluster was selected to carry out for further modeling. The ligand/receptor complexes obtained from the docking procedure was further refined in Amber 14 [38] using the quenched molecular dynamics (QMD) method as previously described [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . According to QMD, the best energy configuration of each complex resulting from this step was subsequently solvated by a cubic box of TIP3P [39] water molecules extending at least 10 Å in each direction from the solute. The system was neutralized and the solution ionic strength was adjusted to the physiological value of 0.15 M by adding the required amounts of Na + and Cl -ions. Each solvated system was relaxed by 500 steps interaction. This analysis was carried out using the MM/GBSA approach [40] , and was based on the same snapshots used in the binding free energy calculation. All simulations were carried out using the Pmemd modules of Amber 14, running on our Mose25 CPU/GPU calculation cluster.
Chemistry
Commercially available chemicals were of reagents grade and used as received. Column chromatography was performed on Silica Gel 60 (230-400 mesh, Merk) and reaction courses and product mixtures were routinely monitored by thin-layer chromatography (TLC) on silica gel precoated F 254 Merck plates. Melting points were determined with a Büchi 510 capillary apparatus or a Stuart SMP300, and are uncorrected. Infrared spectra were recorded on a Perkin
Elmer RXI spectrophotometer in nujol mulls. Proton nuclear magnetic resonance ( In an analogous way the pure isomers (R)-4-phenyloxazolidin-2-one (R)-13 and (S)-4-phenyloxazolidin-2-one (S)-13 were obtained: 
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Synthesis of (R,S)4-phenyloxazolidin-2-one
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(R)-4-phenyloxazolidin-2-one (R)-13
(S)-4-phenyloxazolidin-2-one (S)-13
White solid; m. 
5-Phenyl-1,3,4-oxadiazol-2(3H)-one 14 [43]
To an ice-bath solution of benzoic acid hydrazide (2. [44] 3.00 g (21.0 mmol) of 1-tetralone were dissolved in 120 ml of toluene and cooled with an ice bath at 0°C, under stirring. Sodium azide (2.67 g, 41.0 mmol) was added in one portion and, subsequently, 10.2 ml of H 2 SO 4 conc. were added drop by drop, over a period of 30 minutes.
4,5-Dihydro-1H-benzo[b]]azepin-2(3H)-one 15
The solution was left to stir overnight, then 82 ml of distilled water were slowly added and the organic phase was separated, dried over anhydrous Na 2 SO 4 , filtrate and evaporated in vacuo. 
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Compounds 16-22 are commercially available.
General synthesis of intermediate 23-32
(R,S) 3-(4-bromobutyl)-4-phenyloxazolidin-2-one 23
To a solution of 1.6 g (10.0 mmol) of (R,S) 4-phenyloxazolin-2-one (13) 
In the same way the enantiomerically pure compounds (R)-23, (S)-23 and compounds 24-32
were obtained. 
(R) 3-(4-bromobutyl)-4-phenyloxazolidin-2-one (R)-23
(S) 3-(4-bromobutyl)-4-phenyloxazolidin-2-one (S)-23
3-(4-bromobutyl)-5-Phenyl-1,3,4-oxadiazol-2(3H)-one 24
White solid (upon cooling overnight), yield: 53%; m.p. 60-66 °C; 1 H-NMR: (CDCl3/TMS) δ: 
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1-(4-bromobutyl)-3,4-dihydroquinolin-2(1H)-one 25
Chromatography column (AcOEt- 
4-(4-bromobutyl)-2H-benzo[b][1,4]thiazin-3(4H)-one 27
1-(4-bromobutyl)-2,3,4,5-tetrahydro-1H-benzo[b]]azepin-2(3H)-one 28
2-(4-bromobutyl)isoindoline-1,3-dione 29
This compound has been synthesized starting from potassium phtalimide (1 eq.) and 1,4-dibromobutane (2.5 eq.) by refluxing the mixture in acetone for 6 hours. The hot solution was filtered off from inorganic salts then concentrated in vacuo and recrystallized from n-hexane to afford a white solid. 
1-(4-bromobutyl)indoline-2,3-dione 30
To a solution (1eq.) of isoindolin-1,3-dione in DMF, 1.2eq. of NaH (95%) was added at 0°C and the mixture was stirred for 30 minutes. Then 2.5eq. of 1,4-dibromobutane was slowly added and the mixture was allowed to stir at room temperature overnight. The solution was poured into icecold water and extracted three times with diethyl ether which was collected, dried over anhydrous Na 2 SO 4 , filtered and evaporated. The residue was purified by chromatography column (100% CH 2 Cl 2 ). indol.).
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1-(4-bromobutyl)piperidin-2-one 31
The synthesis of this intermediate started from 1 eq. of piperidin-2-one dissolved in ACN, 5% mol of TBAB and 1.5eq. of CsCO 3 as base. The reaction mixture was allowed to stir overnight at room temperature then the solvent was evaporated under reduced pressure. 
1-(4-bromobutyl)indole 32
The synthesis of this compound was carried out with the same procedure described above for the corresponding indolin-2,3-dione derivative (30) , with the addiction of a catalytic amount (5% mol) of TBAB into the reaction mixture. The product was purified by chromatography column on silica gel using petroleum ether (40°-70°) as eluent to afford a light yellow oil. 
General synthesis of final compounds 2-11a,b
(R,S) 3-(4-Benzyl-(methyl)-amino)-butyl)-4-phenyl-oxazolidin-2-one 2a
A The 1-(4-chlorophenyl)-N-methylmethanamine was synthesized starting from 4-chlorobenzyl chloride (14.0 mmol) and 20 ml of ethanolic solution of methylamine (33%) under reflux for 2h.
The mixture was distilled under vacuum to eliminate the excess of methylamine and washed with a satured NaHCO 3 solution to afford a yellow oil (56%) that was used without further purification.
The 1-(2,4-dimethylphenyl)-N-methylmethanamine was synthesized in analogous way.
(R,S) 3-(4-((4-Chlorobenzyl)-(methyl)-amino)-butyl)-4-phenyl-oxazolidin-2-one 2b.
Starting from 1-(4-chlorophenyl)-N-methylmethanamine and (R,S)-3(4-bromobutyl)-5-
phenyloxazolidin-2-one 23 following the same procedure described above, 70% of 2b was obtained as a yellow pure oil. 
(R) 3-(4-Benzyl-(methyl)-amino)-butyl)-4-phenyl-oxazolidin-2-one (R)-2a
Yellow oil; yield: 83%; I.R.: (nujol, cm -1 ) 1754 (C=O 
(R) 3-(4-((4-Chlorobenzyl)-(methyl)-amino)-butyl)-4-phenyl-oxazolidin-2-one (R)-2b
Yellow oil; yield: 82%; I.R.: (nujol, cm -1 ) 1754 (C=O 
(S) 3-(4-Benzyl-(methyl)-amino)-butyl)-4-phenyl-oxazolidin-2-one (S)-2a
(L) 3-(4-((4-Chlorobenzyl)-(methyl)-amino)-butyl)-4-phenyl-oxazolidin-2-one (S)-2b
Yellow oil; yield: 83%; I.R.: (nujol, cm -1 ) 1754 (C=O). 1 H-NMR: (CDCl 3 -TMS; 500 MHz) δ: 
3-(4-(Benzyl(methyl)amino)butyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one 3a
3-(4-((4-Chlorobenzyl)(methyl)amino)butyl)-5-phenyl-1,3,4-oxadiazol-2(3H)-one 3b
Yellow oil; yield: 47%; I.R.: (nujol, cm 
2-(4-Benzyl(methyl)amino)butyl)-2H-benzo[b][1,4]thiazin-3(4H)-one 6a
2-(4-Benzyl(methyl)amino)butyl)isoindoline-1,3-dione 8a
Yellow oil; yield: 63%; I. 
2-(4-((4-Chlorobenzyl)(methyl)amino)butyl)isoindoline-1,3-dione 8b
Yellow oil; yield: 47%; I.R.: (nujol, cm -1 ) 1715 (C=O 
1-(4-Benzyl(methyl)amino)butyl)indoline-2,3-dione 9a
Trituration with diethyl ether give a reddish oil; yield: 67%; I. 
1-(4-((4-Chlorobenzyl)(methyl)amino)butyl)indoline-2,3-dione 9b
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Materials
The guinea pig brains and rat liver for the σ 1 and σ 2 receptor binding assays were commercially Trilux (all Perkin Elmer LAS, Rodgau-Jügesheim, Germany).
Preparation of membrane homogenates from guinea pig brain:
5 guinea pig brains were homogenized with the potter (500-800 rpm, 10 up-and-down strokes) in volumes of buffer and frozen (−80 °C) in 1.5 ml portions containing about 1.5 mg protein/ml.
Preparation of membrane homogenates from rat liver:
Two rat livers were cut into small pieces and homogenized with the potter (500-800 rpm, 10 upand-down strokes) in 6 volumes of cold 0.32 M sucrose. The suspension was centrifuged at 1200
x g for 10 min at 4 °C. The supernatant was separated and centrifuged at 31,000 x g for 20 min at 4 °C. The pellet was suspended in 5-6 volumes of buffer (50 mM TRIS, pH 8.0) and incubated at room temperature for 30 min. After the incubation, the suspension was centrifuged again at 31000 x g for 20 min at 4 °C. The final pellet was resuspended in 5-6 volumes of buffer and stored at -80°C in 1.5 ml portions containing about 2 mg protein/ml.
Protein determination
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The protein concentration was determined by the method of Bradford [45] , modified by Stoscheck [46] . The Bradford solution was prepared by dissolving 5 mg of Coomassie Brilliant Blue G 250 in 2.5 ml of EtOH (95 %, v/v). 10 ml deionized H 2 O and 5 ml phosphoric acid (85%, m/v) were added to this solution, the mixture was stirred and filled to a total volume of 50.0 ml with deionized water. The calibration was carried out using bovine serum albumin as a standard Crailsheim, Germany).
General procedures for the binding assays:
The During the incubation, the multiplates were shaken at a speed of 500-600 rpm at the specified temperature. Unless otherwise noted, the assays were terminated after 120 min by rapid filtration using the harvester. During the filtration each well was washed five times with 300 µL of water.
Subsequently, the filtermats were dried at 95 °C. The solid scintillator was melted on the dried filtermats at a temperature of 95 °C for 5 minutes. After solidifying of the scintillator at room temperature, the trapped radioactivity in the filtermats was measured with the scintillation M A N U S C R I P T
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transformed into K i -values using the equation of Cheng and Prusoff [47] . The K i -values are given as mean value + SEM from three independent experiments.
Performance of the binding assays
σ 1 receptor
The assay was performed with the radioligand [ 
σ 2 receptor
The assays were performed with the radioligand [ serum (FBS) and Antibiotic Antimycotic Solution (Sigma-Aldrich, 100 U penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B) at 37 °C in a humidified incubator with a 5% CO 2 /95% air atmosphere.
MTT viability assay
The cytotoxic effects of the sigma ligands were evaluated by MTT test on SH-SY5Y cells.
Briefly, cells were plated 1x10 3 cells/well in 96-well plates 24 h prior to treatment with the M A N U S C R I P T
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compounds. The compounds were dissolved in DMSO and serially diluted in culture medium to achieve the desired final concentrations. The final concentration of DMSO in the culture medium was always = 1.0%. After 48 h, 20 µl MTT solution (5mg/ml) was added to each well, and plates were incubated for 4 h at 37°C. Multiwell plates were then read in a iMark™
Microplate Absorbance Reader (Bio-rad). All compounds were assayed in triplicates, and the results derive from at least three independent experiments. Results are presented by mean absorbance (A595 subtracted by A655) ± SD. Statistical analysis was done using one-way ANOVA Test (GraphPad Prism; GraphPad Software, La Jolla, CA). 
